07:18 AM EDT, 03/19/2024 (MT Newswires) -- XORTX Therapeutics Inc. ( XRTX ) , a late-stage clinical pharmaceutical company developing therapies to treat progressive kidney disease, on Tuesday provided an overview of its 2023 achievements.

The company said that In support of pharmaceutical partnership discussions, XORTX initiated an independent commercial assessment of the XRx-008 program for ADPKD with Bluestar BioAdvisors. This evaluation included interviews with 30 nephrologists and 10 payers with large national plans that cover over 290 million lives. This assessment suggests that the XRx-008 program for ADPKD worldwide peak net sales per year may exceed $1 billion, with a total product life estimated to surpass seven to 10 years, the company said.

In 2023, the company made progress advancing its strategic plan in key areas, including chemistry, formulation, manufacturing, and non-clinical studies using XORLO to attenuate polycystic kidney disease (PKD) progression in animal models, and topline results from the XRX-OXY-101 bridging clinical study of XORLO. Each of these milestones permit the next step in the company's clinical development plan, being a registration clinical trial - XRX-OXY-201 in pursuit of accelerated approval and support of the company's lead program XRx-008 program for ADPKD.

The company will shortly provide guidance on 2024 corporate objectives including announcements on clinical and regulatory submissions in support of the XRX-OXY-201 clinical trial.